A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

Score over time

What counts as success

The trial's main goal(s), called the “primary outcome.”

• Parts A and B - Occurrence of dose-limiting toxicities within a participant

  Measured over: First 21 days (Part A) or 28 days (Part B) after the first dose of BNT329.

• Parts A, B, and D - Occurrence of treatment-emergent adverse events (TEAEs), Grade ≥3 TEAEs, serious adverse events (SAEs), treatment-related TEAEs, treatment-related Grade ≥3 TEAEs, and treatment-related SAEs

  Measured over: From first dose of BNT329 until 60 days after the last dose of BNT329 (up to 26 months).

• Parts A, B, and D - Occurrence of dose interruptions, reductions, and discontinuation of BNT329 due to TEAEs

  Measured over: From the time of initiation of the first dose of BNT329 until 60 days after the last dose of BNT329 (up to 26 months).

• Part D - Objective response rate (ORR)

  Measured over: From first dose of BNT329 until end of study (up to approximately 36 months).

Changes Tremor has spotted